Details for Patent: 9,566,336

Title:	In situ gelling drug delivery system
Abstract:	The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.
Inventor(s):	Su; Dongling (Franklin, MA), Ashton; Paul (Newton, MA), Chen; Jianbing (Wayland, MA)
Assignee:	pSivida US, Inc. (Watertown, MA)
Filing Date:	Jul 28, 2014
Application Number:	14/444,338
Claims:	1. A method for forming a polymeric sustained-release drug delivery gel in a subject, comprising injecting into the subject a drug delivery device comprising a fluid composition, wherein: the device comprises a tube; the fluid composition is positioned in the tube; the fluid composition comprises a drug, a biocompatible and bioerodable poly(DL-lactide-glycolide) (PLGA) polymer, and a polyoxyethylene ether; the polyoxyethylene ether serves as a solvent for the PLGA polymer; and the composition forms a gel phase when said composition comes into contact with water or bodily fluids. 2. The method according to claim 1, wherein the composition is co-injected with an aqueous fluid. 3. The method according to claim 2, wherein the aqueous fluid is buffered saline. 4. The method according to claim 1, wherein the device has at least one opening. 5. The method according to claim 1, wherein the device is an open tube. 6. The method according to claim 1, wherein the polyoxyethylene ether is polyethylene glycol (PEG). 7. The method according to claim 6, wherein the average MW of the polyethylene glycol is between about 100 and about 6000. 8. The method according to claim 6, wherein the average MW of the polyethylene glycol is between about 200 and about 400. 9. The method according to claim 1, wherein the drug is a pegylated prodrug. 10. The method of claim 1, wherein the release rate of the drug from the device is dependent on the surface area of the composition that is exposed to water or bodily fluids.